Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus OXYTETRACYCLINE HYDROCHLORIDE.
DOXYCHEL HYCLATE vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic